Ondansetron reduces the craving of biologically predisposed alcoholics

Psychopharmacology
Bankole A JohnsonMadeline Velazquez

Abstract

Early onset alcoholics (EOA) differ from late onset alcoholics (LOA) by having greater serotonergic abnormality, familial history, and a range of antisocial behaviors. Previously, we showed that ondansetron, a selective 5-HT3 antagonist, effectively treated EOA. Proximate motivational drives such as craving could have determined drinking behavior. We therefore investigated whether ondansetron treatment would reduce alcohol craving significantly among EOA. We tested the hypothesis that the craving outcomes of EOA, compared with LOA, would be differentially improved by ondansetron. We also tested the prediction that craving would be significantly correlated with drinking behavior. We studied a cohort of 253 out of 321 enrolled alcohol dependent subjects. These 253 subjects were entered into a 1-week lead-in single-blind placebo period followed by 11 weeks of double-blind outpatient treatment. Study design was a 2 (EOA versus LOA)x 4 medication dose (placebo, or ondansetron 1, 4, or 16 microg/kg b.i.d)x 13 (visits) factorial analysis of variance. Craving was measured at each visit using seven visual analogue scales. Subjects received 12 weekly sessions of standardized group cognitive behavioral therapy. Data reduction by factor an...Continue Reading

Citations

Dec 24, 2002·Human Psychopharmacology
Aug 21, 2012·Journal of Neural Transmission·Christian Jacob
Feb 3, 2009·Neuropsychology Review·Lorenzo LeggioRobert M Swift
Mar 5, 2013·CNS Drugs·Giovanni AddoloratoRaffaele Landolfi
Nov 4, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David P KingPeter W Park
Oct 21, 2011·Nature Reviews. Neuroscience·Markus HeiligCharles P O'Brien
Nov 3, 2005·Journal of Child and Adolescent Psychopharmacology·James G Waxmonsky, Timothy E Wilens
May 3, 2005·Behavioural Pharmacology·S D McKenzie-QuirkK A Miczek
Mar 3, 2005·Neuropsychobiology·Giovanni AddoloratoGiovanni Gasbarrini
Aug 22, 2003·American Journal of Pharmacogenomics : Genomics-related Research in Drug Development and Clinical Practice·Mary-Anne Enoch
Nov 5, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Fabio CaputoMauro Bernardi
Feb 28, 2014·CNS Drugs·Carolina L Haass-KofflerGeorge A Kenna
Feb 12, 2013·Addictive Behaviors·João Maria Corrêa Filho, Danilo Antonio Baltieri
Mar 3, 2010·Annual Review of Clinical Psychology·Kent E Hutchison
Aug 6, 2009·European Archives of Psychiatry and Clinical Neuroscience·Márcia Fonsi ElbrederRonaldo Laranjeira
Apr 19, 2003·International Clinical Psychopharmacology·Stéphane PotvinJean-Yves Roy
Mar 22, 2007·Expert Opinion on Therapeutic Targets·Andrew J Thompson, Sarah C R Lummis
Jun 10, 2011·Expert Opinion on Investigational Drugs·Thomas HillemacherHelge Frieling
Jun 7, 2005·Expert Opinion on Emerging Drugs·Raye Z LittenMark Egli
Sep 1, 2011·Progress in Neurobiology·Philippe HuotJonathan M Brotchie
Mar 2, 2011·Pharmacology & Therapeutics·Tina K Machu
Aug 5, 2010·Child and Adolescent Psychiatric Clinics of North America·Deborah R Simkin, Severin Grenoble
Jul 14, 2010·Pharmacology & Therapeutics·Jutta WalstabBeate Niesler
Mar 16, 2016·Neuroscience and Biobehavioral Reviews·Deepali GuptaMahesh Radhakrishnan
Feb 17, 2005·Alcoholism, Clinical and Experimental Research·George R BreeseFriedbert Weiss
Jul 25, 2003·Alcoholism, Clinical and Experimental Research·Henry R KranzlerCarlos Hernandez-Avila
Dec 24, 2003·Alcoholism, Clinical and Experimental Research·Scott F Stoltenberg
Apr 29, 2004·Alcoholism, Clinical and Experimental Research·William J McBrideBankole A Johnson
Jan 18, 2007·Fundamental & Clinical Pharmacology·Sophie Tambour, Etienne Quertemont
Feb 28, 2006·Alcoholism, Clinical and Experimental Research·Bankole A JohnsonNassima Ait-Daoud
Jun 1, 2005·Addictive Behaviors·Giovanni AddoloratoUNKNOWN Alcoholism Treatment Study Group
Sep 6, 2005·Addictive Behaviors·Suzanne E Thomas, Deborah Deas
Apr 29, 2014·Behavioural Brain Research·Christian P Müller, Judith R Homberg
May 20, 2015·Pharmacology & Therapeutics·A ThompsonM Pirmohamed
Feb 23, 2013·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·João Maria Corrêa Filho, Danilo Antonio Baltieri
Sep 11, 2016·Child and Adolescent Psychiatric Clinics of North America·Christopher J Hammond
Feb 4, 2010·Journal of Psychopharmacology·Ramamoorthy Rajkumar, Radhakrishnan Mahesh
Sep 25, 2017·Alcoholism, Clinical and Experimental Research·Matthew B PomrenzeRobert O Messing
Jul 31, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Kent E HutchisonLyndee Paris
Dec 17, 2005·Synapse·Markus StorvikErkki Tupala
Mar 16, 2007·The Journal of Pharmacology and Experimental Therapeutics·Dirk RüschDouglas E Raines

❮ Previous
Next ❯

Related Concepts

Related Feeds

Addiction

This feed focuses mechanisms underlying addiction and addictive behaviour including heroin and opium dependence, alcohol intoxication, gambling, and tobacco addiction.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.